Unique ID issued by UMIN | UMIN000026764 |
---|---|
Receipt number | R000030726 |
Scientific Title | Multi-Center Clinical Evaluation of the ATTUNE Cementless Rotating Platform Total Knee Arthroplasty In the Japanese Patient Population |
Date of disclosure of the study information | 2017/04/03 |
Last modified on | 2021/10/01 16:07:16 |
Multi-Center Clinical Evaluation of the ATTUNE Cementless Rotating Platform Total Knee Arthroplasty In the Japanese Patient Population
DSJ-2016-07 ATTUNE Cementless CR RP Japan
Multi-Center Clinical Evaluation of the ATTUNE Cementless Rotating Platform Total Knee Arthroplasty In the Japanese Patient Population
DSJ-2016-07 ATTUNE Cementless CR RP Japan
Japan |
Osteoarthritis
Orthopedics |
Others
NO
The primary objective of this study is to examine the change from pre-operative baseline to two year postoperative functional performance improvement for the ATTUNE primary, cementless TKA RP system as measured with the KOOS questionnaire (KOOS-ADL sub-score).
Safety,Efficacy
Knee Injury and Osteoarthritis Outcome Score Activities of Daily Living (KOOS ADL)
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Device,equipment |
Evaluate change from preoperative baseline in post-operative outcomes using additional patient reported measures at 2 years: PKIP (overall and sub-scores), KOOS (overall and sub-scores), AKS and EQ-5D-3L.
22 | years-old | <= |
80 | years-old | >= |
Male and Female
Subjects meeting all of the following specific criteria will be considered for participation in the study:
a) Subject is male or female and between the ages of 22 and 80 years at the time of surgery, inclusive.
b) Subject was diagnosed with NIDJD.
c) Subject, in the opinion of the Investigator, is a suitable candidate for cementless primary TKA using the devices described in this CIP with either resurfaced or non-resurfaced patellae.
d) Subject that is willing to give voluntary, written informed consent to participate in this clinical investigation and authorize the transfer of his/her information to the Sponsor.
e) Subject is currently not bedridden
f) Subject, in the opinion of the Investigator, is able to understand this clinical investigation and is willing and able to perform all study procedures and follow-up visits and co-operate with investigational procedures.
g) Subject is able to read, and comprehend the Informed Consent Document as well as complete the required PROs in Japanese.
Subjects will be excluded from participation in the study if they meet any of the following criteria:
a) The Subject is a woman who is pregnant or lactating.
b) Contralateral knee has already been enrolled in this study
c) Subject had a contralateral amputation.
d) Previous partial knee replacement (unicompartmental, bicompartmental or patellofemoral joint replacement), patellectomy, high tibial osteotomy or primary TKA in affected knee.
e) Subject is currently diagnosed with radicular pain from the spine that radiates into the limb to receive TKA.
f) Subject has participated in a clinical investigation with an investigational product (drug or device) in the last three (3) months.
g) Subject is currently involved in any personal injury litigation, medical-legal or Worker's Accident Insurance claims (similar to Workers Compensation in USA).
h) Subject, in the opinion of the Investigator, is a drug or alcohol abuser (in the last 5 years) or has a psychological disorder that could affect their ability to complete patient reported questionnaires or be compliant with follow-up requirements.
i) Subject was diagnosed and is taking prescription medications to treat a muscular disorder that limits mobility due to severe stiffness and pain such as fibromyalgia or polymyalgia.
j) Subject has a significant neurological or musculoskeletal disorder(s) or disease that may adversely affect gait or weight bearing (e.g., muscular dystrophy, multiple sclerosis, Charcot disease).
k) Subject is suffering from inflammatory arthritis (e.g., rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, etc.).
l) Subject has a medical condition with less than two (2) years life expectancy.
m) Uncontrolled gout
80
1st name | Sue Kemp |
Middle name | |
Last name | Sue Kemp |
DePuy Synthes
Clinical R&D
8DT
DePuy Synthes St. Anthony's Road Leeds LS11 8DT United Kingdom
+4401133877800
skemp1@ITS.JNJ.com
1st name | Miyuki Sakamoto |
Middle name | |
Last name | Miyuki Sakamoto |
Johnson & Johnson K.K. Medical Company
Clinical Development Clinical Operation
101-0065
5-2, Nishi-kanda 3-chome, Chiyoda-ku, Tokyo 101-0065,Japan
03-4411-6457
msakamo5@its.jnj.com
Johnson & Johnson K.K. Medical Company
Johnson & Johnson K.K. Medical Company
Profit organization
Kobe Univ. Hosp. clinical & Translational Research center
Kobe University Hospital 7-5-2 Kusunoki-cho, Chuo-ku, Kobe City,Hyogo Prefecture, JAPAN, 650-0017
078-382-6669
chiken@med.kobe-u.ac.jp
NO
神戸大学医学部附属病院(兵庫県)Kobe University Graduate School of Medicine(Hyogo)、
大阪労災病院(大阪府)Osaka Rosai Hospital(Osaka)、
名古屋市立大学病院(愛知県)Nagoya City University Hospital(Aichi)、
名古屋整形外科人工関節クリニック(愛知県)Nagoya orthopedic Clinic(Aichi)
2017 | Year | 04 | Month | 03 | Day |
Unpublished
Completed
2017 | Year | 01 | Month | 10 | Day |
2017 | Year | 06 | Month | 02 | Day |
2017 | Year | 06 | Month | 30 | Day |
2020 | Year | 12 | Month | 22 | Day |
2021 | Year | 06 | Month | 30 | Day |
2021 | Year | 08 | Month | 31 | Day |
2017 | Year | 03 | Month | 29 | Day |
2021 | Year | 10 | Month | 01 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030726